Celldex Therapeutics (CLDX) Releases Earnings Results, Misses Expectations By $-0.02 EPS

Celldex Therapeutics (CLDX) reported quarterly earnings results on Monday, Aug-8-2016. The company reported $-0.36 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $-0.34. The company posted revenue of $1.40 million in the period, compared to analysts expectations of $.96 million. The company’s revenue was down -36.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.33 EPS.

Celldex Therapeutics opened for trading at $4.51 and hit $4.71 on the upside on Friday, eventually ending the session at $4.66, with a gain of 3.33% or 0.15 points. The heightened volatility saw the trading volume jump to 17,81,171 shares. Company has a market cap of $460 M.

In a different news, on Nov 25, 2015, Avery W Catlin (Sr. VP & CFO) sold 25,000 shares at $18.00 per share price. According to the SEC, on Aug 26, 2015, Larry Ellberger (director) purchased 5,000 shares at $14.00 per share price. On Aug 14, 2015, Anthony S Marucci (CEO) purchased 5,800 shares at $16.81 per share price, according to the Form-4 filing with the securities and exchange commission.

Celldex Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development includes varlilumab also referred to as CDX-1127 a fully human therapeutic monoclonal antibody for cancer indications CDX-1401 a targeted immunotherapeutic for cancer indications and CDX-301 an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.

Celldex Therapeutics

Leave a Reply

Celldex Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celldex Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.